Drug intelligence / Profile preview

WTYX10001

Development stage: Preclinical
Lead developer: WANTAI BioPharm
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

WTYX10001 is a live attenuated varicella vaccine developed by Beijing Wantai Biological Pharmacy and Sino-Innovax Biotech (Xiamen Innovax Biotech) for the prevention of varicella (chickenpox) caused by varicella-zoster virus (VZV) infection. The vaccine is formulated using the live attenuated Oka strain of VZV. In June 2026, Beijing Wantai's marketing authorization application (NDA) for the vaccine was accepted for review by the National Medical Products Administration (NMPA) of China, placing the candidate in the registration phase.

Other names: Varicella Vaccinelive attenuated varicella vaccine

Beyond the preview

Go deeper on WTYX10001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTYX10001.

Explore the full profile